Morpholino

MO1-sp5a

ID

ZDB-MRPHLNO-050901-1

Name

MO1-sp5a

Previous Names

MO1-sp5

Target

sp5a (1)

Sequence

5' - TTCGGAGTGCGATCCTGGAGCAGAA - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

splice-blocker

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO1-sp5a

Expressed Gene	Anatomy	Figures
atoh1a	otic placode	Fig. 12 from Tan et al., 2022
noto	unspecified	Fig. 4 from Weidinger et al., 2005

Phenotype

Phenotype resulting from MO1-sp5a

Phenotype	Fish	Figures
otic placode atoh1a expression decreased amount, abnormal	AB + MO1-sp5a	Fig. 12 from Tan et al., 2022
otic placode atoh1a expression decreased distribution, abnormal	AB + MO1-sp5a	Fig. 12 from Tan et al., 2022

Phenotype of all Fish created by or utilizing MO1-sp5a

Phenotype	Fish	Conditions	Figures
otic vesicle neurog1 expression decreased amount, abnormal	AB + MO1-sp5a	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic vesicle sp5l expression spatial pattern, ameliorated	AB + MO1-sp5a	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic vesicle pax5 expression amount, ameliorated	AB + MO1-sp5a	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic vesicle sp5l expression amount, ameliorated	AB + MO1-sp5a	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic placode atoh1a expression decreased distribution, abnormal	AB + MO1-sp5a	standard conditions	Fig. 12 from Tan et al., 2022
otic vesicle pax5 expression spatial pattern, ameliorated	AB + MO1-sp5a	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic placode atoh1a expression decreased amount, abnormal	AB + MO1-sp5a	standard conditions	Fig. 12 from Tan et al., 2022
presumptive rhombomere 3 GFP expression decreased amount, abnormal	zf1077Tg + MO1-sp5a + MO2-sp5l	standard conditions	Fig. 6 from Labalette et al., 2015
presumptive rhombomere 4 GFP expression decreased amount, abnormal	zf1077Tg + MO1-sp5a + MO2-sp5l	standard conditions	Fig. 6 from Labalette et al., 2015
otic vesicle sp5l expression spatial pattern, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic placode atoh1a expression decreased distribution, abnormal	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	standard conditions	Fig. 12 from Tan et al., 2022
otic vesicle pax5 expression amount, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic vesicle sp5l expression amount, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic vesicle neurog1 expression spatial pattern, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic vesicle neurog1 expression amount, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic placode atoh1a expression decreased amount, abnormal	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	standard conditions	Fig. 12 from Tan et al., 2022
otic vesicle pax5 expression spatial pattern, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022

Citations